Preferred Label : Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130;
NCIt synonyms : CRISPR/Cas9 Gene-edited Allogeneic Anti-CD70 CAR-T Cells CTX130; Donor-derived Gene-edited Allogeneic CAR-T Cells CTX130; Allogeneic CRISPR-Cas9-engineered T Cells CTX130;
NCIt definition : A preparation of human allogeneic T-lymphocytes gene-edited with the clustered regularly
interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt expression
of endogenous TCR and major histocompatibility complex (MHC) class I molecules and
modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated
antigen (TAA) human cluster of differentiation 70 (CD70), with potential immunostimulating
and antineoplastic activities. Upon introduction into the patient, the allogeneic
CRISPR-Cas9 engineered anti-CD70 CAR T-cells CTX130 recognize and bind to CD70-overexpressing
tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing
of CD70-positive tumor cells. CD70, the ligand for the costimulatory receptor CD27
and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of
various types of cancer cells. Disruption of endogenous TCR prevents graft-versus-host
disease (GvHD); the disruption of MHC class I molecules increases the persistence
of the CAR T-cells.;
Molecule name : CTX-130; CTX 130;
NCI Metathesaurus CUI : CL1407020;
Origin ID : C173153;
UMLS CUI : C5417959;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
